During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Keytruda is already approved by the FDA as a first-line therapy for PD-L1-positive metastatic cervical cancer in combination with chemo, with or without bevacizumab, and as a second-line therapy ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

In the global arena of biomedicine, Guangzhou's innovative drug companies are rewriting the rules with "hard‑core technology.

Michelle Patidar, nutrition health coach, explains how matcha, a type of green tea, can help prevent cancer and boost the ...

The five year survival rate for stage 3 (locally spread) and 4 (metastatic) cervical cancer is around 40% and 15%, respectively. The positive KEYNOTE-826 results keeps Merck ahead of rivals in the ...

Discover 7 crucial cancer warning signs often missed during routine medical exams and learn how to recognize these subtle ...

Iovance Biotherapeutics (NASDAQ: IOVA) is one such company right now, entering a decade of incredible growth. Here's why ...